Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Down 53.5% in February

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a significant decline in short interest in February. As of February 15th, there was short interest totalling 10,100 shares, a decline of 53.5% from the January 31st total of 21,700 shares. Based on an average trading volume of 132,000 shares, the short-interest ratio is presently 0.1 days.

Emmaus Life Sciences Stock Up 6.1 %

OTCMKTS EMMA traded up $0.00 during trading hours on Monday, hitting $0.02. 37,484 shares of the company were exchanged, compared to its average volume of 59,380. The company has a 50 day moving average of $0.02 and a two-hundred day moving average of $0.02. The firm has a market cap of $1.12 million, a price-to-earnings ratio of -0.19 and a beta of 6.64. Emmaus Life Sciences has a 52-week low of $0.00 and a 52-week high of $0.13.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.